Fenfluramine

Introduction Overview

Generic Name

fenfluramine

Brand Name

Fintepla

Dosage Form

oral solution

Drug Class

CNS stimulants, Miscellaneous anticonvulsants

Pharmacokinetics

Absorption:

Fenfluramine, the active component of Fintepla, is administered orally as a solution and is readily absorbed from the gastrointestinal tract. The oral solution formulation allows for consistent bioavailability. Absorption is efficient and not significantly affected by food intake, permitting dosing with or without meals. The time to peak plasma concentration (Tmax) is typically observed within a few hours post-dose, allowing relatively rapid onset of therapeutic effects. The absorption profile supports twice-daily dosing regimens adjusted for patient weight and response.

Distribution:

Fenfluramine exhibits extensive tissue distribution, with a volume of distribution that reflects wide penetration into body compartments including the central nervous system, facilitated by its lipophilic properties. It crosses the blood-brain barrier effectively, which is essential for its anticonvulsant activity targeting central serotonergic pathways. Plasma protein binding is moderate, allowing sufficient free drug concentration for receptor engagement. Distribution kinetics support steady-state levels with chronic administration, which is critical in maintaining seizure control.

Metabolism:

Fenfluramine undergoes hepatic metabolism primarily via cytochrome P450 enzymes. It is extensively metabolized into active and inactive metabolites, including norfenfluramine, which has pharmacologic activity relevant to therapeutic and adverse effects. The metabolic pathway involves N-dealkylation and subsequent conjugation reactions such as glucuronidation and sulfation. Genetic polymorphisms and liver function status can influence metabolic rates, affecting drug levels and necessitating dose adjustments or monitoring in hepatic impairment.

Elimination:

The elimination of fenfluramine and its metabolites occurs predominantly via renal excretion with a minor component via biliary routes. The elimination half-life ranges approximately from 20 to 35 hours, supporting a twice-daily dosing schedule. Renal function alterations can impact drug clearance, thus patients with impaired renal function may require careful monitoring or dose modification. The drug's pharmacokinetic profile maintains relatively stable plasma concentrations, minimizing peak-trough fluctuations that could increase seizure risk or adverse effects.

Dosage Forms

Available Dosage Forms:

Fintepla is formulated exclusively as a cherry-flavored oral solution, which facilitates precise dosing and is well-suited for pediatric and adult patients, including those with difficulties swallowing tablets or capsules. The oral solution is administered using a calibrated dosing syringe to ensure accurate weight-based dosing.

Dosages for Adults and Adolescents:

The recommended initial dosage is 0.1 mg/kg administered twice daily. The dose may be cautiously titrated on a weekly basis based on clinical response and tolerability, considering factors such as seizure control, adverse effects, weight changes, and the presence of comorbidities. Dosage adjustments may be necessary for adult patients depending on therapeutic response and safety monitoring outcomes. The dosing ceiling is individualized, but care is taken to avoid doses that might increase the risk of cardiac valvulopathy or pulmonary arterial hypertension.

Specific Patient Populations:

In pediatric patients aged 2 years and older, the dosing is similarly weight-based, starting at 0.1 mg/kg twice daily, with gradual increases guided by therapeutic effect and safety. Due to the risk of cardiac side effects, echocardiographic monitoring is mandated before initiating therapy and periodically during treatment. Patients with hepatic or renal impairment require cautious dosing and close monitoring owing to altered pharmacokinetics. Fintepla has not been established as safe or effective in children under 2 years of age. In patients with weight loss or decreased appetite, dose adjustments or discontinuation may be required.

The oral solution is the sole approved form, emphasizing careful measurement and administration techniques for this specialized population. Administration via gastric and nasogastric feeding tubes is also supported, expanding versatility for patients with feeding difficulties.

Mechanism Of Action

Fenfluramine, the active agent in Fintepla, exerts its anticonvulsant effects predominantly through modulation of the serotonergic system in the central nervous system. Fenfluramine increases serotonin release and inhibits its reuptake, leading to elevated synaptic serotonin levels. This enhanced serotonergic neurotransmission modulates neuronal excitability and seizure thresholds, contributing to seizure control in patients with Dravet syndrome and Lennox-Gastaut syndrome.

At the molecular level, fenfluramine acts as a serotonin releaser by inducing vesicular release of serotonin from presynaptic neurons. It also serves as a weak serotonin reuptake inhibitor, prolonging serotonin availability in synaptic clefts. Furthermore, fenfluramine and its active metabolite norfenfluramine interact with multiple serotonin receptor subtypes, including 5-HT2 receptors, which play roles in modulating cortical excitability. This multimodal interaction modulates neuronal networks that are hyperexcitable in epileptic syndromes.

Beyond serotonergic pathways, fenfluramine may indirectly influence GABAergic and glutamatergic neurotransmission, which are critical in seizure pathophysiology. These modulatory effects potentially normalize aberrant excitatory and inhibitory balance in epileptic brain circuits. Its ability to impact multiple neurotransmitter systems differentiates fenfluramine from other anticonvulsants, providing a unique therapeutic profile beneficial for refractory epilepsies.

Clinically, these mechanisms translate into significant reduction of seizure frequency and severity in patients with Dravet syndrome and Lennox-Gastaut syndrome, as demonstrated in controlled clinical trials. Comparative studies suggest that fenfluramine's serotonergic enhancement is distinctive among anticonvulsants, providing efficacy in cases unresponsive to traditional GABAergic or sodium channel blocker therapies. Ongoing research continues to elucidate its precise molecular targets and the relationship between serotonin dynamics and epileptic seizure control.

Pharmacological Actions

Increases synaptic serotonin levels by promoting serotonin release and inhibiting reuptake
Modulates serotonin 5-HT2 receptor activity affecting neuronal excitability
Enhances inhibitory neurotransmission and normalizes excitatory-inhibitory balance in the CNS
Exerts anticonvulsant effects in refractory epileptic syndromes such as Dravet and Lennox-Gastaut syndromes
Displays a unique mechanism differing from classical antiepileptic drugs by targeting serotonergic pathways
May influence secondary neurotransmitter systems including GABA and glutamate indirectly
Reduces seizure frequency and severity in pediatric and adult patients
Demonstrates central nervous system stimulant properties as part of its pharmacodynamic profile
Potential to cause cardiovascular effects due to serotonergic action on heart valves and pulmonary vasculature
Acts as a Schedule IV controlled substance with potential for misuse though low abuse liability

Therapeutic Or Clinical Uses

Treatment of seizures associated with Dravet syndrome in patients aged 2 years and older
Management of seizures in Lennox-Gastaut syndrome for pediatric and adult populations
Adjunctive therapy option for drug-resistant epilepsies characterized by severe seizure phenotypes
Reduction in seizure frequency and improvement of seizure control quality in treated individuals
Therapy suitable across a broad age range including children, adolescents, and adults
Potential to improve quality of life in patients with catastrophic epileptic encephalopathies
Used in patients where other antiepileptic agents have proven insufficient or poorly tolerated
Approved for oral administration allowing flexible dosing and ease of use
Prescribed under a restricted REMS program due to risks of cardiac valvulopathy and pulmonary hypertension
Utilized in specialized epilepsy clinics with multidisciplinary care for monitoring and dose titration

Side Or Adverse Effects

Abnormal echocardiogram findings indicative of possible valvular heart disease
Constipation and gastrointestinal disturbances including diarrhea and vomiting
Decreased appetite leading to weight loss, requiring regular weight monitoring
General fatigue, low energy, and weakness which may impact daily functioning
Drowsiness, sedation, and lethargy, especially when combined with other CNS depressants or alcohol
High blood pressure requiring regular monitoring during treatment
Increased drooling and difficulties with movement, balance, and walking
Respiratory infections and fever, potentially due to immunomodulatory effects
Risk of serotonin syndrome characterized by mental status changes, hypertension, muscle rigidity, and hyperthermia
Glaucoma with symptoms such as eye pain, vision changes, halos around lights, and nausea
Falls possibly related to impaired coordination or sedation
Potential for suicidal thoughts or behavior in rare cases requiring close mental health monitoring
Other hypersensitivity reactions including allergic responses to fenfluramine or excipients
Discontinuation symptoms including increased seizure frequency if treatment is stopped abruptly

Precautions

Monitor cardiac function with regular echocardiograms due to risk of valvular heart disease and pulmonary arterial hypertension
Avoid use with concomitant serotoninergic drugs such as SSRIs, SNRIs, MAOIs, and serotonin agonists to prevent serotonin syndrome
Regularly assess blood pressure throughout treatment and manage hypertension if it arises
Perform ongoing weight and nutritional assessments due to appetite suppression and potential weight loss
Be vigilant for signs of glaucoma and promptly evaluate ocular complaints
Advise caution when engaging in activities requiring alertness until drug effects on sedation are known
Use caution in patients with pre-existing liver or kidney impairment due to altered fenfluramine metabolism and clearance
Gradually taper dose when discontinuing therapy to prevent seizure exacerbation or status epilepticus
Screen for history of mood disorders or suicidal ideation and monitor mental health during treatment
Ensure strict adherence to the Fintepla REMS program requirements to manage safety risks
Utilize caution in patients with a history of substance abuse given fenfluramine's controlled substance status
Inform patients and caregivers about the importance of dose accuracy using the provided dosing syringe
Avoid use in patients allergic to fenfluramine or any inactive ingredients
Pregnant and breastfeeding women should consult healthcare providers due to lack of safety data
Store medication properly to prevent degradation and accidental ingestion by children

Warnings

Contraindicated in patients with known hypersensitivity to fenfluramine or inactive ingredients
High risk of valvular heart disease necessitates echocardiographic monitoring prior to and throughout treatment
Pulmonary arterial hypertension is a serious potential adverse effect requiring vigilance for respiratory symptoms
Serotonin syndrome is a potentially life-threatening condition with symptoms including mental status changes and autonomic instability
Should not be used concurrently or within 14 days of monoamine oxidase inhibitors, serotonin agonists, or selective serotonin reuptake inhibitors
May increase blood pressure necessitating regular monitoring and management
May cause sedation or lethargy; patients should avoid activities such as driving until responses to the drug are assessed
Possibility of suicidal ideation or behavior; patients should be closely monitored for mood changes
Abrupt discontinuation can worsen seizure control; taper dosing under medical supervision
Risk of glaucoma with sudden vision changes or eye pain requires immediate medical attention
Controlled substance status (Schedule IV) due to potential for abuse and dependence
Use during pregnancy only if the potential benefit justifies potential risk; consult pregnancy registry if exposure occurs
Not established safe or effective in children under 2 years of age
Do not share medication; misuse may lead to serious harm or legal consequences
Overdose may result in serious adverse events warranting emergency evaluation

Contraindication

Hypersensitivity to fenfluramine or any inactive ingredient in Fintepla
Concomitant use with or within 14 days of stopping monoamine oxidase inhibitors (MAOIs)
Concurrent use with other serotonin agonists or selective serotonin reuptake inhibitors (SSRIs)
Presence of untreated or severe valvular heart disease
Established diagnosis of pulmonary arterial hypertension
Patients with a history of allergic reactions to fenfluramine or related compounds
Children younger than 2 years of age due to safety and efficacy unknown
Use in patients with significant hepatic or renal impairment without specialist assessment
Patients unable or unwilling to comply with required cardiac monitoring protocols
Use in pregnancy unless the benefits outweigh potential risks
Known or suspected drug abuse or dependency without close medical supervision
Situations where monitoring facilities for blood pressure and cardiac function are not accessible
Interaction with drugs that strongly inhibit or induce CYP enzymes affecting fenfluramine metabolism
Patients with previously documented history of serotonin syndrome
Use in patients with narrow-angle glaucoma without ophthalmologic evaluation and clearance

Drug Interactions

Selective serotonin reuptake inhibitors (SSRIs) increase risk of serotonin syndrome
Serotonin-norepinephrine reuptake inhibitors (SNRIs) elevate serotonergic effects and risk
Tricyclic antidepressants (TCAs) may potentiate serotonergic toxicity
Monoamine oxidase inhibitors (MAOIs) are contraindicated due to severe serotonin syndrome risk
Serotonin receptor agonists such as triptans can precipitate serotonin syndrome
Antipsychotic medications may interact altering CNS effects or seizure threshold
Clobazam may require dose adjustments when used concomitantly
Cyproheptadine, a serotonin antagonist, may reduce fenfluramine efficacy
Dextromethorphan combined usage increases serotonin syndrome risk
Lithium may have pharmacodynamic interactions affecting mood and seizure control
St. John's Wort as an herbal supplement can alter fenfluramine metabolism
Stiripentol affects metabolism pathways and can modify fenfluramine plasma levels
Tramadol concomitant use enhances serotonergic effects and seizure risk
Tryptophan supplements increase risk of serotonin syndrome
Other CNS depressants, including alcohol, enhance sedation and drowsiness

Preparations Of The Drug

Fintepla oral solution, cherry flavored, provided in a calibrated dosing syringe
Fenfluramine hydrochloride as the active pharmaceutical ingredient
Inactive ingredients include citric acid, ethylparaben, hydroxyethylcellulose, methylparaben, potassium citrate, sucralose, cherry flavor, and purified water
Formulated without gluten-containing grains such as wheat, barley, or rye
Packaged with instructional leaflet detailing dosage measurement and administration
Bottled for room temperature storage with clear indications on discard times post opening
Available only through the FDA-approved Fintepla REMS program to ensure safety monitoring
Dosing syringes designed for pediatric and adult weight-based dosing accuracy
No tablet or capsule form; oral solution facilitates administration through feeding tubes if necessary
Manufactured and distributed by UCB, adhering to stringent quality control and regulatory standards
Packaging includes safety features to prevent unintended use or diversion
Storage instructions specify maintaining temperature between 68°F to 77°F (20°C to 25°C)
Discard any unused medication three months after opening to maintain potency and safety
Product labeling strongly emphasizes controlled substance status and legal dispensing restrictions
Provided with supporting educational materials for healthcare providers and patients